Cargando…

In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for hospital acquired pneumonia

The in vitro activity of tigecycline was evaluated against 819 baseline pathogens isolated from 383 patients enrolled in the phase 3 clinical trial investigating the efficacy of tigecycline in hospital acquired pneumonia (HAP). The trials were global, enrolling patients in 27 countries. Tigecycline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersen, Peter J., Tuckman, Margareta, Jones, C. Hal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892572/ https://www.ncbi.nlm.nih.gov/pubmed/24470884 http://dx.doi.org/10.4081/idr.2010.e1

Ejemplares similares

Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin
por: Ramirez, Julio A, et al.
Publicado: (2012)

Tigecycline Versus Levofloxacin in Hospitalized Patients With Community-Acquired Pneumonia: An Analysis of Risk Factors
por: Dartois, Nathalie, et al.
Publicado: (2013)

Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia
por: Townsend, Mary L, et al.
Publicado: (2011)

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
por: Tanaseanu, Cristina, et al.
Publicado: (2009)

Temporal trends of the in vitro activity of tigecycline and comparator antibiotics against clinical aerobic bacterial isolates collected in Germany, 2006–2014: results of the Tigecycline Evaluation and Surveillance Trial (TEST)
por: Kresken, Michael, et al.
Publicado: (2016)

Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
por: Zhou, Yangang, et al.
Publicado: (2019)

Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii
por: Liu, Ben, et al.
Publicado: (2020)

Characterization of Tigecycline Resistance Among Tigecycline Non-susceptible Klebsiella pneumoniae Isolates From Humans, Food-Producing Animals, and in vitro Selection Assay
por: Moghimi, Mohaddeseh, et al.
Publicado: (2021)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

In Vitro Activity of Tigecycline Against Orientia tsutsugamushi
por: Lee, Sun-Myoung, et al.
Publicado: (2016)

In Vitro Activity of Tigecycline and Colistin against clinical isolates of Acinetobacter baumannii in Hospitals in Tehran and Bandar-Abbas, Iran
por: peerayeh, Shahin najar, et al.
Publicado: (2014)

Genomic characterization of tigecycline-resistant Escherichia coli and Klebsiella pneumoniae isolates from hospital sewage
por: Li, Ying, et al.
Publicado: (2023)

In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia
por: Cikman, Aytekin, et al.
Publicado: (2015)

Tigecycline Resistant Klebsiella pneumoniae Isolated from Austrian River Water
por: Hladicz, Alexander, et al.
Publicado: (2017)

First Emergence of acrAB and oqxAB Mediated Tigecycline Resistance in Clinical Isolates of Klebsiella pneumoniae Pre-Dating the Use of Tigecycline in a Chinese Hospital
por: Zhong, Xue, et al.
Publicado: (2014)

In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates
por: KARAMANLIOĞLU, Dilek, et al.
Publicado: (2019)

Tigecycline Susceptibility and the Role of Efflux Pumps in Tigecycline Resistance in KPC-Producing Klebsiella pneumoniae
por: He, Fang, et al.
Publicado: (2015)

Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo
por: Pearce, Camron, et al.
Publicado: (2020)

The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates
por: Nulsopapon, Parnrada, et al.
Publicado: (2021)

The Resistance Mechanism and Clonal Distribution of Tigecycline-Nonsusceptible Klebsiella pneumoniae Isolates in Korea
por: Ahn, Chulsoo, et al.
Publicado: (2016)

Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem‐resistant Klebsiella pneumoniae isolates
por: Park, Yumi, et al.
Publicado: (2020)

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013
por: Hoban, Daryl J, et al.
Publicado: (2015)

Clinical Efficacy, Antibiotic Resistance Genes, Virulence Factors and Outcome of Hospital-Acquired Pneumonia Induced by Klebsiella pneumoniae Carbapenemase 2-Producing with Tigecycline Treatment in the ICU
por: Bai, Xiang-Rong, et al.
Publicado: (2022)

Characterization of Tigecycline-Heteroresistant Klebsiella pneumoniae Clinical Isolates From a Chinese Tertiary Care Teaching Hospital
por: Zhang, Qiaoyu, et al.
Publicado: (2021)

A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae
por: Sun, Lilan, et al.
Publicado: (2022)

In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy
por: Mezzatesta, Maria Lina, et al.
Publicado: (2008)

In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from skin and soft tissue infections
por: Mohanty, Srujana, et al.
Publicado: (2021)

Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials
por: Tucker, Hal, et al.
Publicado: (2017)

Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates
por: Stein, Claudia, et al.
Publicado: (2015)

In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
por: Ahmed, Nahid H, et al.
Publicado: (2012)

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
por: Stefani, Stefania, et al.
Publicado: (2016)

The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016
por: Decousser, Jean-Winoc, et al.
Publicado: (2018)

Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment
por: Wang, Fangzhou, et al.
Publicado: (2021)

In vitro activities of antifungals alone and in combination with tigecycline against Candida albicans biofilms
por: Hacioglu, Mayram, et al.
Publicado: (2018)

In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis
por: Sun, Xiang, et al.
Publicado: (2021)

Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)
por: Kuti, Joseph L., et al.
Publicado: (2019)

Proteomics Study of the Synergistic Killing of Tigecycline in Combination With Aminoglycosides Against Carbapenem-Resistant Klebsiella pneumoniae
por: Ma, Xinqian, et al.
Publicado: (2022)

421. In vitro and in vivo synergistic antimicrobial activities of the combinations of meropenem, colistin, tigecycline, and ceftolozane/tazobactam against carbapenem-resistant Klebsiella pneumoniae
por: Yoon, Young Kyung, et al.
Publicado: (2022)

Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient
por: Al-Qadheeb, Nada S., et al.
Publicado: (2010)

Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae
por: Ni, Wentao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mrhpgp4a81dc360epkhs60d4a3